Investor Profile: KdT Ventures — Thesis, Cheque Size & How to Apply

KdT Ventures is an Austin, Texas based venture firm that invests at the intersection of frontier science and technology, and it likes to be the first institutional investor in the room. Founded in 2017 by physician scientist Cain McClary, the firm backs companies turning advances in chemistry, biology and computation into real products, from therapeutics and diagnostics to industrial biotechnology and agriculture. Its team calls itself a group of scientific athletes, with nine advanced degrees and 48 years of combined scientific and clinical training.

Investment thesis

The firm's thesis is that advances in computation are making it possible to solve problems that were never before addressable, particularly in the life sciences. It focuses on reprogramming chemistry and biology using creative technology platforms, and it describes science as the source code of reality, from atoms to algorithms. That means it is comfortable with deep technical risk, long timelines and companies that look more like research programmes than software startups in their early days. Its portfolio spans therapeutics, digital health, industrial biotechnology, chemicals, materials and climate, and it follows its companies through their lifecycles rather than treating seed as a single transaction.

Sectors and stages

KdT Ventures focuses predominantly on pre-seed and seed deals, with the intent and ability to follow on through Series A and beyond. Initial cheques range from $500,000 to $5 million. Its fourth fund, Fund IV, closed in October 2024 at over $100 million, oversubscribed, following an $80 million Fund III and a $50 million fund closed in 2021. Aggregate assets under management crossed $250 million after the Fund IV close. The firm is headquartered in Austin, Texas, with a presence in Research Triangle, North Carolina, and it invests across the United States, with portfolio companies also in Europe.

Notable portfolio / track record

The firm's portfolio now includes more than 65 companies. Among the names it highlights are PathAI, which applies artificial intelligence to pathology; Solugen, which manufactures chemicals using biology rather than petrochemicals; Dyno Therapeutics, which designs gene therapy capsids using machine learning; and Abridge, which uses artificial intelligence to document clinical conversations. Its earlier portfolio included Checkerspot, Azitra and Elemental Machines, and more recent investments include Character Biosciences, SURGE Therapeutics, March Bio and 54gene, the African genomics company.

How to apply for funding

KdT Ventures does not operate a public application portal, but it does publish a direct contact route: founders can email the firm at [email protected], the address given in its own fund announcements. A strong approach will lead with the science, clearly and without hype: what is the technical breakthrough, what evidence exists so far, and what experiment or milestone would de-risk the company next. Because the firm aims to be the first institutional investor, it is a natural fit for teams coming out of university labs or research institutions who have not yet raised institutional capital.